Congress’s Medicare Deal Isn’t a Deal at All

Democrats and Republicans are touting a permanent “doc fix,” but they’ve yet to reach agreement on the hardest part: how to pay for it.

The opening session of the 113th Congress. (Rick Bloom)
National Journal
Clara Ritger
Feb. 6, 2014, 7:51 a.m.

Demo­crats and Re­pub­lic­ans are tout­ing a com­prom­ise that would re­peal a flawed for­mula that de­term­ines Medi­care phys­i­cian pay­ments, but for now it’s a deal in name only.

Law­makers in both cham­bers are plan­ning to in­tro­duce bi­par­tis­an le­gis­la­tion Thursday to re­peal Medi­care’s Sus­tain­able Growth Rate for­mula, a phys­i­cian pay­ment plan Con­gress passed in 1997 in the hopes of lim­it­ing spend­ing on the massive so­cial pro­gram. Since 2003, however, Con­gress has passed short-term patches to stop the cuts, a mad­den­ing an­nu­al tra­di­tion known as the “doc fix” that has come at a cost of roughly $150 bil­lion.

In an ef­fort to end the an­nu­al ex­er­cise, the bills law­makers are re­leas­ing Thursday would re­peal the SGR for­mula and would in­sti­tute five years of an­nu­al up­dates of 0.5 per­cent to Medi­care phys­i­cians’ pay.

But des­pite the bills’ bi­par­tis­an back­ing, law­makers have yet to agree on the thorn­i­est is­sue of the doc fix: how to pay for it.

Neither bill in­cludes meas­ures to off­set the spend­ing — a hole that could sink it among the Hill’s budget hawks. And as Con­gress de­bates where to cut or where to get new rev­en­ue to off­set the spend­ing, the deal’s bi­par­tis­an sup­port could splinter.

The Con­gres­sion­al Budget Of­fice is slated to do a cost es­tim­ate of the meas­ures Thursday af­ter­noon, be­fore they are form­ally un­veiled.

If it were to pass, the com­prom­ise le­gis­la­tion as cur­rently writ­ten would cre­ate a pro­gram and qual­ity meas­ures to eval­u­ate per­form­ance and re­ward pro­viders who im­prove health out­comes, and it adds in­cent­ives for care co­ordin­a­tion for pa­tients with chron­ic con­di­tions. Ad­di­tion­ally, it cre­ates a Phys­i­cian Com­pare web­site that Medi­care be­ne­fi­ciar­ies can use to make de­cisions about pro­viders, as well as to al­low out­side re­view­ers to eval­u­ate qual­ity of care.

This year’s round of phys­i­cian re­im­burse­ment cuts is set to take ef­fect in March, un­less Con­gress acts.

What We're Following See More »
SEVEN-POINT LEAD IN A FOUR-WAY
Quinnipiac Has Clinton Over 50%
2 hours ago
THE LATEST

Hillary Clinton leads Donald Trump 51%-41% in a new Quinnipiac poll released today. Her lead shrinks to seven points when the third-party candidates are included. In that scenario, she leads 45%-38%, with Gary Johnson pulling 10% and Jill Stein at 4%.

Source:
PROCEDURES NOT FOLLOWED
Trump Not on Ballot in Minnesota
4 hours ago
THE LATEST
MIGHT STILL ACCEPT FOREIGN AND CORPORATE MONEY
Chelsea to Stay on Board of Clinton Foundation
4 hours ago
THE LATEST

Is the Clinton family backtracking on some of its promises to insulate the White House from the Clinton Foundation? Opposition researchers will certainly try to portray it that way. A foundation spokesman said yesterday that Chelsea Clinton will stay on its board, and that the "foundation’s largest project, the Clinton Health Access Initiative, might continue to accept foreign government and corporate funding."

Source:
INTERCEPT IN MIDDLE EAST
Navy Calls Iranian Ships’ Actions Dangerous, Unprofessional
5 hours ago
THE LATEST

"Four Iranian ships made reckless maneuvers close to a U.S. warship this week, the Pentagon said Thursday, in an incident that officials said could have led to dangerous escalation." The four Iranian vessels engaged in a "high-speed intercept" of a U.S. destroyer in the Strait of Hormuz. A Navy spokesman said the Iranina actions "created a dangerous, harassing situation that could have led to further escalation including additional defensive measures" by the destroyer.

Source:
$300 SAVINGS CARD
Under Pressure, EpiPen Maker Drops Prices
6 hours ago
THE LATEST

Amid public outcry and the threat of investigation by the Senate Judiciary Committee, Mylan has agreed to effectively drop the price of EpiPens. "The company, which did not lower the drug's list price, said it would reduce the patient cost of EpiPen through the use of a savings card, which will cover up to $300 of EpiPen 2-Pak."

Source:
×